Panacea Biotec Receives Demand Order for ₹22.88 Crore

Panacea Biotec Receives Demand Order for ₹22.88 Crore

Panacea Biotec Receives Demand Order for ₹22.88 Crore​

Panacea Biotec Limited announced it received a Demand Order dated March 30, 2026, from the Office of the Joint Commissioner, Central Goods & Services Tax (CGST) Sub-Commissionerate Mohali, Chandigarh. The demand aggregates to approximately ₹22.88 crore, encompassing ₹11.44 crore for alleged non-payment of Goods and Services Tax and ₹11.44 crore in penalties.

The demand stems from a previous Show Cause Notice received on September 27, 2025, concerning the alleged non-payment of GST on a corporate guarantee of ₹864 crore provided for 1,074 days, from April 6, 2019, to March 15, 2022. The company filed a writ petition with the Punjab & Haryana High Court in November 2025, which has granted an interim stay order preventing coercive action against the company. Panacea Biotec also submitted a response to the Show Cause Notice on March 27, 2026.

According to the company, the demand is not maintainable, and they will take necessary steps. The company does not anticipate a relevant impact on its financial, operational or other activities.



Details of the Demand Order:

ParticularsDetails
Name of the Listed EntityPanacea Biotec Limited
Date of Receipt of CommunicationMarch 30, 2026
Demand Amount~₹22.88 Crore (₹11.44 Crore GST + ₹11.44 Crore Penalty)
Period of Alleged Non-PaymentApril 6, 2019 to March 15, 2022
Actions TakenFiled a writ petition with the Punjab & Haryana High Court; submitted response to Show Cause Notice

Source:​

 

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.

Last edited by a moderator:
Back
Top